Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France

References

• Knight DR, Elliott B, Chang BJ, et al. Diversity and evolution in the genome of Clostridium difficile. Clin Microbiol Rev 2015;28:721-41
   PubMed Web of Science ®Google Scholar
• Lessa FC, Winston LG, McDonald LC; Emerging Infections Program C. difficile Surveillance Team. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:2369-70
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55
   PubMed Web of Science ®Google Scholar
• Wiegand PN, Nathwani D, Wilcox MH, et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012;81:1-14
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(Suppl 2):1-26
   Google Scholar
• Bouza E, Dryden M, Mohammed R, et al.; for the Polymer Alternative for CDAD Treatment (PACT) Investigators. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin Microbiol Infect 2008;14(Suppl 7):S103-S4
   Google Scholar
• Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al.; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31
   PubMed Web of Science ®Google Scholar
• Cornely OA, Miller MA, Fantin B, et al. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 2013;31:2493-9
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nat Rev Gastroenterol Hepatol 2011;8:330-9
   PubMed Web of Science ®Google Scholar
• Mullane KM, Cornely OA, Crook DW, et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol 2013;38:1-11
   PubMed Web of Science ®Google Scholar
• Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324-33
   PubMed Web of Science ®Google Scholar
• Eyre DW, Walker AS, Wyllie D, et al.; Infections in Oxfordshire Research Database. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012;55(Suppl 2):S77-87
   PubMed Web of Science ®Google Scholar
• Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011;53:440-7
   PubMed Web of Science ®Google Scholar
• Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 2012;18(Suppl 6):5-12
   PubMed Web of Science ®Google Scholar
• Escobar GJ, Baker M, Li SX, et al. Clinical and economic burden of recurrent Clostridium difficile infections - a 10-year retrospective large database analysis. ICAAC, Washington DC, September 5–9, 2014 [Abstract K-362]
   Google Scholar
• Heimann SM, Vehreschild JJ, Cornely OA, et al. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection 2015;43:707-14
   PubMed Web of Science ®Google Scholar
• Chaparro-Rojas F, Mullane KM. Emerging therapies for Clostridium difficile infection – focus on fidaxomicin. Infect Drug Resist 2013;6:41-53
   PubMedGoogle Scholar
• Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010;156:3354-9
   PubMed Web of Science ®Google Scholar
• Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Inf Dis 2012;55(Suppl 2):S132-S42
   PubMed Web of Science ®Google Scholar
• Cornely OA, Crook DW, Esposito R, et al.; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-9
   PubMed Web of Science ®Google Scholar
• Cornely OA, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014;69:2892-2900
   PubMed Web of Science ®Google Scholar
• L’Assurance Maladie 2015. Base des médicaments à code UCD, February 1, 2012. http://www.ameli.fr/professionnels-de-sante/directeurs-d-etablissements-de-sante/codage/medicaments/base-des-medicaments-a-code-ucd.php. Accessed June 15, 2015
   Google Scholar
• ISPOR Global Health Care Systems Road Map 2009. http://www.ispor.org/htaroadmaps/france.asp#1. Accessed June 15, 2015
   Google Scholar
• Haute autorité de santé. Choix méthodologiques pour l’évaluation économique à la HAS. http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf. Accessed June 15, 2015
   Google Scholar
• Inspection Générale des Affaires Sociales. Evaluation médico-économique en santé. 2014. http://www.igas.gouv.fr/IMG/pdf/2014-066R_-_Rapport_DEF.pdf. Accessed June 15, 2015
   Google Scholar
• Bartsch SM, Umscheid CA, Fishman N, et al. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 2013;57:555-61
   PubMed Web of Science ®Google Scholar
• Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013;16:297-304
   PubMed Web of Science ®Google Scholar
• Nathwani D, Cornely OA, Van Engen AK, et al. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014;69:2901-12
   PubMed Web of Science ®Google Scholar
• Watt M, McCrea C, Johal S, et al. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Infection 2016;44:599-606
   PubMed Web of Science ®Google Scholar
• Konijeti GG, Sauk J, Shrime MG, et al. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014;58:1507-14
   PubMed Web of Science ®Google Scholar
• Crook DW, Walker SA, Kean Y, et al. Fidaxomicin versus vancomycin for clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Inf Dis 2012;55(Suppl 2):S93-S103
   PubMed Web of Science ®Google Scholar
• Briggs A, University of Oxford. Parametric survival models and decision models: relating continuous hazards to discrete-time transition probabilities. 2004. http://www.herc.ox.ac.uk/conferences-and-presentations/presentationfilelinks/abw151004. Accessed June 15, 2015
   Google Scholar
• French National Life Tables. French national life tables Eurostat. 2014. http://ec.europa.eu/eurostat/web/main/home. Accessed March 16, 2015
   Google Scholar
• Coignard B, Hébert M, Eckert C, et al. Epidemiological and microbiological characteristics of Clostridium difficile infections, France, 2009: a national, multicentre, prospective survey. Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases; Vienna, Austria; 10-13 April 2010
   Google Scholar
• Karas JA, Enoch DA, Aliyu SH. A review of mortality due to Clostridium difficile infection. J Infect 2010;61:1-8
   PubMed Web of Science ®Google Scholar
• Yoon YK, Kim MJ, Sohn JW, et al. Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy. Support Care Cancer 2014;22:2039-48
   PubMed Web of Science ®Google Scholar
• Le Monnier A, Duburcq A, Zahar J-R, et al., on behalf of the GMC study Group. Hospital cost of Clostridium difficile infection in French acute-care hospitals: the impact of recurrences. J Hosp Infect 2015;91:117-22
   PubMed Web of Science ®Google Scholar
• L’Assurance Maladie. Tarifs conventionnels des médecins généralistes en France métropolitaine, 27 April 2015. http://www.ameli.fr/professionnels-de-sante/medecins/votre-convention/tarifs/tarifs-conventionnels-des-medecins-generalistes/tarifs-des-medecins-generalistes-en-metropole.php. Accessed June 15, 2015
   Google Scholar
• Guillemin I, Marrel A, Lambert J, et al. Patients’ experience and perception of hospital-treated Clostridium difficile infections: a qualitative study. Patient 2014;7:97-105
   PubMedGoogle Scholar
• Hautmann MG, Hipp M, Kölbl O. Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment? Radiat Oncol 2011;6:89
   PubMed Web of Science ®Google Scholar
• Di Bella S, Capone A, Musso M, et al. Clostridium difficile infection in the elderly. Infez Med 2013;21:93-102
   PubMedGoogle Scholar
• Garey KW, Aitken SL, Gschwind L, et al. Development and validation of a Clostridium difficile health-related quality-of-life questionnaire. J Clin Gastroenterol 2016;50:631-7
   PubMed Web of Science ®Google Scholar
• Le F, Arora V, Shah DN, et al. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy 2012;32:129-34
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Polyzos KA, Patouni K, et al. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012;40:1-8
   PubMed Web of Science ®Google Scholar
• Johnson S, Louie TJ, Gerding DN. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014;59:345-54
   PubMed Web of Science ®Google Scholar
• Public Health England. Updated guidance on the management and treatment of Clostridium difficile infection. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/321891/Clostridium_difficile_management_and_treatment.pdf. Accessed July 17, 2015
   Google Scholar
• Figueroa I, Johnson S, Sambol SP, et al. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Inf Dis 2012;55(Suppl 2):S104-S9
   PubMed Web of Science ®Google Scholar